DK1002055T3 - Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning - Google Patents

Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning

Info

Publication number
DK1002055T3
DK1002055T3 DK98938765T DK98938765T DK1002055T3 DK 1002055 T3 DK1002055 T3 DK 1002055T3 DK 98938765 T DK98938765 T DK 98938765T DK 98938765 T DK98938765 T DK 98938765T DK 1002055 T3 DK1002055 T3 DK 1002055T3
Authority
DK
Denmark
Prior art keywords
virus
cell culture
recovery
saline solution
hypertonic saline
Prior art date
Application number
DK98938765T
Other languages
English (en)
Inventor
Michael Denis Johnston
Roderic Simon O'keeffe
Original Assignee
Xenova Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10817061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1002055(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xenova Res Ltd filed Critical Xenova Res Ltd
Application granted granted Critical
Publication of DK1002055T3 publication Critical patent/DK1002055T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16651—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98938765T 1997-08-07 1998-08-07 Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning DK1002055T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9716611.0A GB9716611D0 (en) 1997-08-07 1997-08-07 Virus preparations and methods
EP98938765A EP1002055B2 (en) 1997-08-07 1998-08-07 Recovery of virus from cell culture using a hypertonic salt solution
PCT/GB1998/002387 WO1999007834A1 (en) 1997-08-07 1998-08-07 Recovery of virus from cell culture using a hypertonic salt solution

Publications (1)

Publication Number Publication Date
DK1002055T3 true DK1002055T3 (da) 2004-10-25

Family

ID=10817061

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98938765T DK1002055T3 (da) 1997-08-07 1998-08-07 Indvinding af virus fra cellekultur under anvendelse af en hypertonisk saltoplösning

Country Status (11)

Country Link
EP (1) EP1002055B2 (da)
JP (2) JP2001512675A (da)
AT (1) ATE270325T1 (da)
AU (1) AU8737298A (da)
CA (1) CA2299628A1 (da)
DE (1) DE69824856T2 (da)
DK (1) DK1002055T3 (da)
ES (1) ES2224422T3 (da)
GB (1) GB9716611D0 (da)
PT (1) PT1002055E (da)
WO (1) WO1999007834A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
AU2003297041B2 (en) * 2002-12-13 2009-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
EP1608762B1 (en) 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
CN100398642C (zh) * 2003-06-20 2008-07-02 迈克必斯生物系统公司 病毒生产的改进
AU2004249802B2 (en) * 2003-06-20 2007-06-28 Microbix Biosystems Inc. Improvements in virus production
PT1651666E (pt) 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
DK2947149T3 (da) 2007-06-21 2018-06-06 Alphavax Inc Alphavirus-replikonpartikler til anvendelse i vaccination
KR101624089B1 (ko) 2012-11-22 2016-05-24 아사히 가세이 메디컬 가부시키가이샤 고감염가의 파보바이러스의 생산 방법
CN104250639A (zh) * 2013-06-28 2014-12-31 北京奥源和力生物技术有限公司 一种收获和生产病毒的方法
RU2701948C1 (ru) 2015-11-06 2019-10-02 Асахи Касеи Медикал Ко., Лтд. Способ получения парвовируса, характеризующегося высоким титром инфекционности и высокой чистотой
US10626376B2 (en) 2016-11-14 2020-04-21 St. Jude Children's Research Hospital Method for isolating and purifying adeno-associated virus particles using salt
BR112022025251A2 (pt) * 2020-07-10 2023-01-17 Boehringer Ingelheim Int Processo para produzir rabdovírus purificado a partir de cultura celular

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204257A (en) * 1991-04-29 1993-04-20 Autogen Instruments, Inc. Method of recovering bacteriophage
CZ289574B6 (cs) * 1992-06-04 2002-02-13 Merck And Co., Inc. Způsob výroby ľivé, atenuované vakcíny viru varicella zoster

Also Published As

Publication number Publication date
DE69824856D1 (de) 2004-08-05
GB9716611D0 (en) 1997-10-08
EP1002055B1 (en) 2004-06-30
DE69824856T2 (de) 2005-07-21
EP1002055A1 (en) 2000-05-24
JP2001512675A (ja) 2001-08-28
PT1002055E (pt) 2004-10-29
WO1999007834A1 (en) 1999-02-18
AU8737298A (en) 1999-03-01
CA2299628A1 (en) 1999-02-18
JP2009297036A (ja) 2009-12-24
ES2224422T3 (es) 2005-03-01
EP1002055B2 (en) 2010-04-14
ATE270325T1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
EA200200604A1 (ru) Производство вакцин
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
PT1002055E (pt) Recuperacao de virus a partir de culturas celulares utilizando uma solucao salina hipertonica
CY1110716T1 (el) Πολλαπλασιασμος ιων εντος κυτταροκαλλιεργειας
CY1108113T1 (el) Μεθοδος διαγνωσεως ιν vitro της μολυνσεως απο σιρκoïο χοιρων τυπου ιι και αντιδραστηρια διαγνωσεως
EA199800746A1 (ru) Способ генерации противовирусного иммунного ответа у человека или животного
EA200101186A1 (ru) Регуляция экспрессии вирусных генов
EA200500448A1 (ru) Способ культивирования первичных клеток и амплификации вирусов в бессывороточных условиях
EA200100955A1 (ru) 4-ОКСО-4,7-ДИГИДРОТИЕНО [2,3-b]ПИРИДИН-5-КАРБОКСАМИДЫ В КАЧЕСТВЕ АНТИВИРУСНЫХ СРЕДСТВ
ATE116637T1 (de) Sulfonische stilbenderivate zur behandlung von viruserkrankungen.
HUP0000992A2 (hu) Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai
RU2012146775A (ru) Вирусная частица, высвобождающаяся после инфицирования клеток млекопитающих цитомегаловирусом человека (hcmv), содержащая слитый белок, и ее применение
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
RU2018101139A (ru) Фармацевтические препараты для лечения вирусных инфекций глаза
EA200300215A1 (ru) Вакцинация против вирусов герпеса, ассоциированных с хозяйской клеткой
ES2038689T3 (es) Procedimiento de cultivo del virus de la rinotraqueitis infecciosa de la pava, y vacuna preparada a partir del virus asi obtenido.
EP0666751A4 (en) HEPATITIS A VIRUS VACCINE.
ES336810A1 (es) Un metodo para producir una cepa de celulas.
AR012944A1 (es) Preparacion de virus de la enfermedad de marek usando lineas de celulas continuas de mamifero
EP1073461A4 (en) VIRAL CHIMERES FROM CAEV AND HIV-1 GENETIC ELEMENTS
CN105561303B (zh) 单纯疱疹病毒i型ul5基因缺失的dna疫苗的制备方法
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
KR20070120088A (ko) 바이러스 제제 및 방법
RU94042470A (ru) Поливалентная вакцина для профилактики болезни марека и способ ее изготовления